4 Result: Sanofi
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
June 15th, 2026
First disease modifying therapy approval for new onset stage 3 diabetes represents a significant milestone for the pediatric type 1 diabetes community Silver Spring, MD / CRWE PRESS RELEASE / June 15, 2026 - On June 12, 2026, the U.S. F. Read more
Acuity Brands Posts Mixed Results; Sanofi, Teva Ink Anti-TL1A Therapy Deal
October 04th, 2023
Acuity Brands, Inc. (NYSE: AYI) posted fourth-quarter fiscal 2023 earnings of $3.97 per share, surpassing the consensus EPS estimate of $3.72. Quarterly sales for the company totaled $1.01 billion, slightly below analysts' revenue projections of $1.0. Read more
Breaking: Sanofi's Legal Win, Innovative Eyewear's License Deal
June 20th, 2023
Shares of Sanofi (Nasdaq: SNY) surged in pre-market trading following the announcement of a favorable outcome in an International Chamber of Commerce dispute. The tribunal ruled in favor of Sanofi, dismissing Boehringer Ingelheim's. Read more
Innate Pharma, Sanofi: FDA Grants FTD to SAR'579/IPH6101; Hyzon Motors Posts Q1 Loss - IPHA, HYZN News
June 08th, 2023
Innate Pharma (Nasdaq: IPHA) shared important news from Sanofi (Nasdaq: SNY) regarding the U.S. Food and Drug Administration (FDA) granting Fast Track Designation for SAR'579 / IPH6101 to treat hematological malignancies. The FDA's Fast Trac. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login